Novo Nordisk Gets Downbeat Diagnosis as Investors Prefer Eli Lilly

As the race to create the next generation of weight-loss drugs intensifies, investors are looking to rival Eli Lilly

By Charles Daly · Bloomberg

As the race to create the next generation of weight-loss drugs intensifies, investors are looking to rival Eli Lilly